Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
NEW YORK, Nov. 02, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Mylan N.V. securities and purchasers of Mylan N.V.’s predecessor, Mylan Inc., securities (NASDAQ:MYL) from February 28, 2013 through October 7, 2016, both dates inclusive (the “Class Period”).
To join the Mylan class action, go to http://www.rosenlegal.com/cases-967.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Mylan N.V. and Mylan Inc. incorrectly classified EpiPen® (“EpiPen”) as a generic under the Medicaid Drug Rebate Program, which was financially consequential for federal and state governments as it reduced the amount of quarterly rebates Mylan N.V. and Mylan Inc. owed for EpiPen; (2) between 2011 through 2015, Mylan N.V. and Mylan Inc. paid a lower rebate of 13% when it should have been paying a higher rebate of 23.1% or more; (3) the incorrect classification appears to have cost the federal government more than $100 million in the last five years alone; (4) in turn, Mylan N.V. and Mylan Inc. lacked effective internal controls over financial reporting; and (5) as a result, Mylan N.V. and Mylan Inc.’s public statements were materially false and misleading at all relevant times. The lawsuit claims that investors suffered damages when these details entered the market.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 12, 2016. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-967.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
